Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Asset Writedowns and Impairment (2021 - 2025)

Rapid Micro Biosystems' Asset Writedowns and Impairment history spans 5 years, with the latest figure at $429000.0 for Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $429000.0; the TTM value through Sep 2025 reached $448000.0, up 371.58%, while the annual FY2024 figure was $95000.0, 179.41% up from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 was $429000.0 at Rapid Micro Biosystems, up from $19000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $429000.0 in Q3 2025 and bottomed at $6000.0 in Q3 2021.
  • The 5-year median for Asset Writedowns and Impairment is $41500.0 (2022), against an average of $92500.0.
  • The largest annual shift saw Asset Writedowns and Impairment skyrocketed 2733.33% in 2022 before it crashed 77.65% in 2025.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $16000.0 in 2021, then skyrocketed by 568.75% to $107000.0 in 2022, then crashed by 68.22% to $34000.0 in 2023, then plummeted by 70.59% to $10000.0 in 2024, then soared by 4190.0% to $429000.0 in 2025.
  • Per Business Quant, the three most recent readings for RPID's Asset Writedowns and Impairment are $429000.0 (Q3 2025), $19000.0 (Q1 2025), and $10000.0 (Q2 2024).